軒竹生物科技股份有限公司 董事會薪酬與考核委員會職責和議事規則 第一章 總則 第二章 委員會組成 第六條 委員會由不少於三名董事組成，其中獨立非執行董事應過半數。 第八條 委員會任期與同屆董事會任期一致，委員任期與董事任期一致。委 員任期屆滿，可連選連任。如有委員會委員在任職期間不再擔任公 司董事職務或應當具有獨立非執行董事身份的委員不再具備《香港上 市規則》所規定的獨立性時，其委員資格自動喪失，並由董事會根據 本細則規定補足委員人數。 第九條 委員會委員可以在任期屆滿以前向董事會提出辭職，辭職報告中應 當就辭職原因以及需要公司董事會予以關注的事項進行必要說明。 當委員會人數低於本規則規定最低人數時，在董事會候補的委員就 任前，辭職委員應當繼續履行相關職責。 第十條 經董事長提議並經董事會討論通過，可對委員會委員在任期內進行 調整。 第十一條 委員會委員須向委員會披露以下事項： （一） 在委員會將予決定的任何事宜中擁有的任何個人財務利益（以 本公司股東身份而擁有的利益除外）； （二） 因兼任其他公司的董事職務而產生的任何潛在利益衝突。 2 委員會委員由董事長、半數以上獨立董事或三分之一以上全體董事 提名，董事 ...

董事會審計委員會職責和議事規則 第一章 總則 軒竹生物科技股份有限公司 第二章 委員會組成 第四條 委員會由不少於三名董事組成，且應僅由非執行董事組成，其中獨 立非執行董事應過半數。委員會委員應當具備與其職責相適應的財 務或者法律等方面的專業知識和商業經驗。應至少有一名成員具備 適當的專業資格、會計或相關的財務管理專長，符合《香港上市規 則》對委員會財務專業人士的資格要求。 董事會應定期對委員會成員的獨立性和表現進行評估，必要時更換 不適合留任的成員。公司現任外部審計機構的前合夥人在其從現任 外部審計機構離職或不再享有現任外部審計機構的財務利益之日（以 日期較後者為準）起兩年內不得擔任委員會委員。 第五條 委員會委員由董事長、半數以上獨立非執行董事或三分之一以上全 體董事提名，董事會選舉並由全體董事的過半數通過產生。 1 第一條 為建立和規範軒竹生物科技股份有限公司（以下簡稱「公司」）審計制 度和程序，強化董事會（以下簡稱「董事會」）決策功能，確保董事 會對經理層的有效監督，完善公司治理結構，根據《中華人民共和 國公司法》等有關法律、行政法規、規範性文件（合稱「國家法律法 規」）《香港聯合交易所有限公司證券上 ...

軒竹生物科技股份有限公司 章程 （H股發行後適用） 1 | 目錄 | | --- | | 第一章 | 總則 | 3 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 4 | | 第三章 | 股份 | 4 | | | 第一節 股份發行 | 4 | | | 第二節 股份增減和回購 | 7 | | | 第三節 股份轉讓 | 8 | | 第四章 | 股東和股東會 | 10 | | | 第一節 股東 | 10 | | | 第二節 股東會的一般規定 | 16 | | | 第三節 股東會的召集 | 19 | | | 第四節 股東會的提案與通知 | 20 | | | 第五節 股東會的召開 | 22 | | | 第六節 股東會的表決和決議 | 26 | | 第五章 | 董事會 | 30 | | | 第一節 董事 | 30 | | | 第二節 獨立董事 | 34 | | | 第三節 董事會 | 37 | | 第六章 | 總經理及其他高級管理人員 | 44 | | 第七章 | 監事會 | 46 | | | 第一節 監事 | 46 | | | 第二節 監事會 | 47 | | 第八章 | 財務會計制度、 ...

Core Viewpoint - Shuanglu Pharmaceutical's associate company, Xuan Zhu Bio, is expected to officially list on the Hong Kong Stock Exchange on October 15, 2025, with a global offering of 67.335 million shares priced at HKD 11.60 per share [1] Summary by Relevant Sections - **Company Holdings** - Shuanglu Pharmaceutical holds a total of 1.7808 million shares in Xuan Zhu Bio, which is expected to represent 0.34% of the total shares post-issuance [1] - **Lock-up Period** - The lock-up period for Shuanglu Pharmaceutical's shares in Xuan Zhu Bio will last for 12 months following the company's listing [1]

Core Viewpoint - Shuanglu Pharmaceutical (002038.SZ) announced that its associate company, Xuan Zhu Bio (02575), is expected to officially list on the Hong Kong Stock Exchange on October 15, 2025, with a global offering of 67.335 million shares priced at HKD 11.60 per share [1] Company Summary - Shuanglu Pharmaceutical holds a total of 1.7808 million shares in Xuan Zhu Bio, which is expected to represent 0.34% of the total shares post-issuance [1] - The lock-up period for the shares held by Shuanglu Pharmaceutical will last for 12 months following the listing of Xuan Zhu Bio [1]

格隆汇10月13日丨双鹭药业(002038.SZ)公布，参股公司轩竹生物科技股份有限公司（简称"轩竹生物"） 预计于2025年10月15日正式在联交所挂牌上市，股份代号为02575.HK。根据轩竹生物全球发售招股书 之披露，其本次全球发售6733.35万股，发售价格为每股11.60港元。轩竹生物本次发售完成后，本公司 持有的其股份总数为178.08万股，预计占其发行后总股份数的0.34%，本公司持有的轩竹生物股份的禁 售期为轩竹生物上市后12个月。 ...

格隆汇10月13日｜双鹭药业公告称，公司参股公司轩竹生物预计于2025年10月15日正式在联交所挂牌上 市，股份代号为02575.HK。本次全球发售6733.35万股，发售价格为每股11.60港元。双鹭药业预计持有 其发行后总股份数的0.34%，禁售期为上市后12个月。 ...

北京双鹭药业发布公告，其参股公司轩竹生物预计2025年10月15日在香港联交所主板挂牌上市，股份代 号02575.HK。本次全球发售6733.35万股，发售价格每股11.60港元。发售完成后，双鹭药业持轩竹生物 178.08万股，预计占发行后总股份数的0.34%，禁售期12个月。按规定，双鹭药业将所持轩竹生物股权 划分为"以公允价值计量且其变动计入当期损益的金融资产"。轩竹生物上市预计对双鹭药业2025年财务 与经营成果产生积极影响，具体以审计结果为准。 ...

Industry Dynamics - Nvidia is hosting the 2025 Global Summit on Open Computing, and Oracle is unveiling its AI World Conference [7] - The 138th Canton Fair will be held in three phases in Guangzhou [7] - A revised Anti-Unfair Competition Law will take effect on October 15, enhancing fair competition rules in the digital economy [7] - TSMC is set to announce its earnings [8] - The 2025 World Intelligent Connected Vehicles Conference will take place in Beijing [8] Company News - Xuan Bamboo Biotechnology-B (02575.HK) is set to be listed on October 15 [9] - Yunji (02670.HK) will be listed on October 16, along with earnings announcements from China Tower and Fuyao Glass [10] - Zijin Mining will release its earnings on October 17, and Haixi New Drug (02637.HK) will be listed [11]

Core Viewpoint - The IPO of Xuan Zhu Bio-B (02575.HK), a subsidiary of Sihuan Pharmaceutical, is a significant step in the company's innovative research and development strategy, attracting market attention amid a favorable environment for the pharmaceutical/biotech sector [1] Business Positioning and Pipeline Layout - Xuan Zhu Bio focuses on innovation-driven drug development and commercialization, targeting areas such as digestive system diseases, oncology, and NASH (non-alcoholic steatohepatitis) [2] - The company has over ten drug assets at various stages, including three products with NDA approval, one project in NDA registration, one in Phase III clinical trials, and several in Phase I or with IND approval [2] - Core products include: - KBP-3571: An innovative proton pump inhibitor for digestive diseases, already commercialized - XZP-3287: A CDK4/6 inhibitor for breast cancer (HR+/HER2−), NDA approved - XZP-3621: An ALK inhibitor for non-small cell lung cancer (NSCLC), NDA approved [2] Financial Status and Operating Conditions - In 2022, the company had negligible revenue, with revenue starting to appear in 2023 at approximately several tens of millions of RMB, and a slight increase expected in 2024, but still not profitable [3] - The company is experiencing significant losses, with high R&D expenditures contributing to the losses, and cash flow issues evident with a negative operating cash flow of -95.76 million RMB as of June 2025 and only about 8.558 million RMB in cash [3] IPO Highlights and Fundraising Arrangements - Key IPO details include: - Offering price: HKD 11.60 per share - Total shares offered: 67.33 million H-shares - Public offering ratio: 10% (approximately 6.73 million shares) - Total fundraising amount: approximately HKD 781 million - Market capitalization post-listing: approximately HKD 6.008 billion [5][6] Valuation Levels and Comparative Perspectives - The IPO pricing corresponds to a total market capitalization of approximately HKD 6.008 billion, indicating a potentially aggressive valuation in the current high-risk/high-expectation environment for new drugs [6][7] Industry Trends - The pharmaceutical sector is increasingly driven by themes and expectations, with new stocks often experiencing significant speculative trading on their debut [8] Competitive Landscape and Barriers - The innovative drug development process is characterized by high risks, long cycles, and high costs, with a high failure rate; delays or failures in pipeline projects can lead to significant expectation risks [9] Summary of Risks - The company is currently unprofitable, and its future profitability remains uncertain, which is critical for market valuation acceptance [10] - The company faces cash flow risks due to weak cash reserves and negative operating cash flow, which could hinder operational progress if financing becomes difficult [12] - There are risks associated with pipeline advancement, clinical trials, and regulatory approvals, as many projects are still in early to mid-stages [12] - The company operates in a highly policy-dependent environment, where changes in healthcare negotiations and pricing policies could impact profit margins [13]